Helen Parry

Senior Clinical Lecturer/Associate Professor

University of Birmingham

United Kingdom

Research Interests

Explore related searches

Professors in United Kingdom Professors in Immunology Immunology professors in United Kingdom

Contact this professor

Get a free first email built on one of their papers, ready for you to edit and send yourself.

About

Helen Parry serves as a Senior Clinical Lecturer and Associate Professor at the University of Birmingham in the United Kingdom. Her research focuses on immunological responses in patients with chronic lymphocytic leukaemia (CLL), particularly concerning COVID-19 and vaccination efficacy. Recent publications include studies on PD-1 expression in NK cells and the immunogenicity of various COVID-19 vaccines among older populations.

Articles (11)

Year:

2024

Year:

2022

Year:

2021

Year:

2021

Year:

2021

Year:

2021

Year:

2021

Year:

2021

Year:

2021

Year:

2021

Year:

2020

Collaborators (4)

Suchitra Sundaram

Assistant Professor

Icahn School of Medicine at Mount Sinai

UNITED STATES

View details

Grace Tyson

University of Glasgow

UNITED KINGDOM

View details

Graham McIlroy

NIHR Academic Clinical Lecturer in Haematology

University of Birmingham

UNITED KINGDOM

View details

Matthew Wilson

University of Glasgow

UNITED KINGDOM

View details

ApplyKite TwinLearns as you apply

Make your next move.

Prepare your application

Review drafts before you send them.

Helen Parry

Research Interests

Explore related searches

Contact this professor

About

Articles (11)

PD-1 expression contributes to functional impairment of NK cells in patients with B-CLL

Impaired neutralisation of SARS-CoV-2 delta variant in vaccinated patients with B cell chronic lymphocytic leukaemia.

COVID-19 in patients with CLL: improved survival outcomes and update on management strategies.

mRNA vaccination in people over 80 years of age induces strong humoral immune responses against SARS-CoV-2 with cross neutralization of P.1 Brazilian variant.

Differential immunogenicity of BNT162b2 or ChAdOx1 vaccines after extended-interval homologous dual vaccination in older people.

Immunogenicity of single vaccination with BNT162b2 or ChAdOx1 nCoV-19 at 5-6 weeks post vaccine in participants aged 80 years or older: an exploratory analysis.

Antibody responses after first and second Covid-19 vaccination in patients with chronic lymphocytic leukaemia.

Cross reactivity of serological response to SARS-CoV-2 vaccination with viral variants of concern detected by lateral flow immunoassays.

PD-1 is imprinted on cytomegalovirus-specific CD4+ T cells and attenuates Th1 cytokine production whilst maintaining cytotoxicity

Robust antibody responses in 70-80-year-olds 3 weeks after the first or second doses of Pfizer/BioNTech COVID-19 vaccine, United Kingdom, January to February 2021.

Outcomes of COVID-19 in patients with CLL: a multicenter international experience.

Collaborators (4)

Suchitra Sundaram

Grace Tyson

Graham McIlroy

Matthew Wilson

Make your next move.